Download PDF
Endoscopy 2001; 33(1): 1-7
DOI: 10.1055/s-2001-11182
Review
© Georg Thieme Verlag Stuttgart · New York

Diagnosis of Esophagogastric Tumors

M. Moretó
  • Gastroenterology Unit, Hospital de Cruces, Baracaldo, Spain
Further Information

Publication History

Publication Date:
31 December 2001 (online)

Also available at
    Permissions and Reprints

The incidence of esophageal tumors, and of adenocarcinoma in particular, has risen markedly in recent years in the developed countries. The use of a variety of histopathological and biological markers is now offering promising prospects for the future. Vertical tumor invasion, intratumoral microvessel density, antimucin monoclonal antibodies, flow cytometry, telomerase activity, and overexpression of cyclin D1 have been correlated with the staging and prognosis of esophageal carcinomas. By combining these markers with Lugol staining, a practical new method of staging esophageal tumors may become available in the coming years.

As is well known, Barrett's mucosa is a preneoplastic condition. Discussions in the literature concerning short forms of Barrett's esophagus and their relationship to inflammation of the gastric cardia appear to describe two different scenarios - a gastroesophageal reflux condition for short forms of Barrett's esophagus, and an inflammatory phenomenon (perhaps unrelated to Helicobacter pylori infection) for inflammation of the gastric cardia. Cost-benefit studies of follow-up procedures in Barrett's esophagus have yet to be conducted, and considerable efforts - mainly using biological markers - are being made to identify those patients who are at greatest risk.

Although the frequency of gastric tumors has declined in recent years, many as yet unclear aspects of these tumors have been studied. Technological progress has not led to substantial changes in the diagnostic procedures used, although autofluorescence methods and three-dimensional reconstruction have been analyzed. Laparoscopy, preferably combined with the use of ultrasound probes, may be a valuable tool for staging. The suggestion that endoscopy should be avoided in young patients (the “treat but do not scope” approach) has been seriously questioned, as it may lead to early cancer being overlooked. There is thought to be an intermediate stage of gastric cancer (between the early and advanced stages) in which the muscularis propria, but not the serosa, is invaded. Endoscopic ultrasonography is becoming increasingly established as a basic tool for the staging of gastric cancer. Gastric MALT lymphoma can be cured by H. pylori eradication therapy in many cases, but there is still uncertainty regarding the limitations of this approach.

References

  • 1 Daly J M, Fry W A, Little A G, et al. Esophageal cancer: results of an American College of Surgeons patient care evaluation study.  J Am Coll Surg. 2000;  19 562-572
    PubMedGoogle Scholar
  • 2 Lagergren J, Bergstrom R, Nyren O. Association between body mass and adenocarcinoma of the esophagus and gastric cardia.  Ann Intern Med. 1999;  13 883-890
    PubMedGoogle Scholar
  • 3 Lagergren J, Nyren O. No association between colon cancer and adenocarcinoma of the oesophagus in a population-based cohort study in Sweden.  Gut. 1999;  44 819-821
    PubMedGoogle Scholar
  • 4 Tajima Y, Nakanishi Y, Ochiai A, et al. Histopathologic findings predicting lymph node metastasis and prognosis of patients with superficial esophageal carcinoma: analysis of 240 surgically resected tumors.  Cancer. 2000;  88 1285-1293
    CrossrefPubMedGoogle Scholar
  • 5 Millikan K W, Mall J W, Myers J A, et al. Do angiogenesis and growth factor expression predict prognosis of esophageal cancer?.  Am Surg. 2000;  66 401-405
    PubMedGoogle Scholar
  • 6 Shih C H, Ozawa S, Ando N, et al. Vascular endothelial growth factor expression predicts outcome and lymph node metastasis in squamous cell carcinoma of the esophagus.  Clin Cancer Res. 2000;  6 1161-1168
    PubMedGoogle Scholar
  • 7 Torres C, Wang H, Turner J, et al. Prognostic significance and effect of chemoradiotherapy on microvessel density (angiogenesis) in esophageal Barrett's esophagus-associated adenocarcinoma and squamous cell carcinoma.  Hum Pathol. 1999;  3 753-758
    PubMedGoogle Scholar
  • 8 Sagara M, Yonezawa S, Nagata K, et al. Expression of mucin 1 (MUC1) in esophageal squamous-cell carcinoma: its relationship with prognosis.  Int J Cancer. 1999;  84 251-257
    CrossrefPubMedGoogle Scholar
  • 9 Watanabe M, Kuwano H, Tanaka S, et al. Flow cytometric DNA analysis is useful in detecting multiple genetic alterations in squamous cell carcinoma of the esophagus.  Cancer. 1999;  85 2322-2328
    CrossrefPubMedGoogle Scholar
  • 10 Koyanagi K, Ozawa S, Ando N, et al. Telomerase activity as an indicator of malignant potential in iodine-nonreactive lesions of the esophagus.  Cancer. 2000;  88 1524-1529
    CrossrefPubMedGoogle Scholar
  • 11 Kagawa Y, Yoshida K, Hirai T, et al. Microsatellite instability in squamous cell carcinomas and dysplasias of the esophagus.  Anticancer Res. 2000;  2 213-217
    PubMedGoogle Scholar
  • 12 Safatle-Ribeiro A V, Ribeiro U J r, Sakai P, et al. Integrated p53 histopathologic/genetic analysis of premalignant lesions of the esophagus.  Cancer Detect Prev. 2000;  24 13-23
    PubMedGoogle Scholar
  • 13 Tanaka M, Nonogaki S, Alberti V N, Forones N M. p53 in epidermoid cancer of the esophagus.  Hepatogastroenterology. 1999;  46 1765-1768
    PubMedGoogle Scholar
  • 14 Toyoda H, Nakamura T, Shinoda M, et al. Cyclin D1 expression is useful as a prognostic indicator for advanced esophageal carcinomas, but not for superficial tumors.  Dig Dis Sci. 2000;  45 864-869
    CrossrefPubMedGoogle Scholar
  • 15 Shiozaki H, Doki Y, Kawanishi K, et al. Clinical application of malignancy potential grading as a prognostic factor of human esophageal cancers.  Surgery. 2000;  127 552-561
    CrossrefPubMedGoogle Scholar
  • 16 Arber N, Gammon M D, Hibshoosh H, et al. Overexpression of cyclin D1 occurs in both squamous carcinomas and adenocarcinomas of the esophagus and in adenocarcinomas of the stomach.  Hum Pathol. 1999;  3 1087-1092
    PubMedGoogle Scholar
  • 17 D'Errico A, Barozzi C, Fiorentino M, et al. Role and new perspectives of transforming growth factor-alpha (TGF-alpha) in adenocarcinoma of the gastro-oesophageal junction.  Br J Cancer. 2000;  82 865-870
    CrossrefPubMedGoogle Scholar
  • 18 Menzel J, Hoepffner N, Nottberg H, et al. Preoperative staging of esophageal carcinoma: miniprobe sonography versus conventional endoscopic ultrasound in a prospective histopathologically verified study.  Endoscopy. 1999;  31 291-297
    Article in Thieme ConnectPubMedGoogle Scholar
  • 19 Mallery S, Van Dam J. Increased rate of complete EUS staging of patients with esophageal cancer using the nonoptical, wire-guided echoendoscope.  Gastrointest Endosc. 1999;  5 53-57
    PubMedGoogle Scholar
  • 20 Shinkai Y, Niwa Y, Arisawa T, et al. Evaluation of prognosis of squamous cell carcinoma of the esophagus by endoscopic ultrasonography.  Gut. 2000;  47 120-125
    CrossrefPubMedGoogle Scholar
  • 21 Yamamuro E M, Cecconello I, Iriya K, et al. Lugol dye endoscopy for analysis of esophageal mucosa in achalasia.  Hepatogastroenterology. 1999;  46 1687-1691
    PubMedGoogle Scholar
  • 22 Fagundes R B, de Barros S G, Putten A, et al. Occult dysplasia is disclosed by Lugol chromoendoscopy in alcoholics at high risk for squamous cell carcinoma of the esophagus.  Endoscopy. 1999;  31 281-285
    Article in Thieme ConnectPubMedGoogle Scholar
  • 23 O'Connor J B, Falk G W, Richter J E. The incidence of adenocarcinoma and dysplasia in Barrett's esophagus: report on the Cleveland Clinic Barrett's Esophagus Registry.  Am J Gastroenterol. 1999;  94 2037-2042
    PubMedGoogle Scholar
  • 24 Thurberg B L, Duray P H, Odze R D. Polypoid dysplasia in Barrett's esophagus: a clinicopathologic, immunohistochemical, and molecular study of five cases.  Hum Pathol. 1999;  3 745-752
    PubMedGoogle Scholar
  • 25 Polkowski W, van Lanschot J J, ten Kate F J, et al. Intestinal and pancreatic metaplasia at the esophagogastric junction in patients without Barrett's esophagus.  Am J Gastroenterol. 2000;  95 617-625
    CrossrefPubMedGoogle Scholar
  • 26 Sharma P, Weston A P, Morales T, et al. Relative risk of dysplasia for patients with intestinal metaplasia in the distal oesophagus and in the gastric cardia.  Gut. 2000;  46 9-13
    CrossrefPubMedGoogle Scholar
  • 27 Rudolph R E, Vaughan T L, Storer B E, et al. Effect of segment length on risk for neoplastic progression in patients with Barrett esophagus.  Ann Intern Med. 2000;  132 612-620
    PubMedGoogle Scholar
  • 28 Weston A P, Badr A S, Hassanein R S. Prospective multivariate analysis of clinical, endoscopic, and histological factors predictive of the development of Barrett's multifocal high-grade dysplasia or adenocarcinoma.  Am J Gastroenterol. 1999;  94 3413-3419
    CrossrefPubMedGoogle Scholar
  • 29 Nilsson J, Skobe V, Johansson J, et al. Screening for oesophageal adenocarcinoma: an evaluation of a surveillance program for columnar metaplasia of the oesophagus.  Scand J Gastroenterol. 2000;  35 10-16
    CrossrefPubMedGoogle Scholar
  • 30 Provenzale D, Schmitt C, Wong J B. Barrett's esophagus: a new look at surveillance based on emerging estimates of cancer risk.  Am J Gastroenterol. 1999;  94 2043-2053
    CrossrefPubMedGoogle Scholar
  • 31 Gimenez A, Minguela A, de Haro L M, et al. DNA ploidy status and proliferative activity as markers of malignant potential in Barrett's esophagus: flow cytometric study using routinely paraffin-embedded tissue.  World J Surg. 2000;  24 72-77
    CrossrefPubMedGoogle Scholar
  • 32 Younes M, Lechago J, Chakraborty S, et al. A Relationship between dysplasia, p53 protein accumulation, DNA ploidy, and Glut1 overexpression in Barrett metaplasia.  Scand J Gastroenterol. 2000;  35 131-137
    CrossrefPubMedGoogle Scholar
  • 33 Sarbia M, Bektas N, Muller W, et al. Expression of cyclin E in dysplasia, carcinoma, and nonmalignant lesions of Barrett esophagus.  Cancer. 1999;  86 2597-2601
    CrossrefPubMedGoogle Scholar
  • 34 Chinyama C N, Marshall R E, Owen W J, et al. Expression of MUC1 and MUC2 mucin gene products in Barrett's metaplasia, dysplasia and adenocarcinoma: an immunopathological study with clinical correlation.  Histopathology. 1999;  35 517-524
    CrossrefPubMedGoogle Scholar
  • 35 Van Laethem J L, Peny M O, et al. et al . Intramucosal adenocarcinoma arising under squamous re-epithelialisation of Barrett's oesophagus.  Gut. 2000;  46 574-577
    CrossrefPubMedGoogle Scholar
  • 36 Garewal H, Ramsey L, Sharma P, et al. Biomarker studies in reversed Barrett's esophagus.  Am J Gastroenterol. 1999;  94 2829-2833
    CrossrefPubMedGoogle Scholar
  • 37 Gotoda T, Saito D, Kondo H, et al. Endoscopic and histological reversibility of gastric adenoma after eradication of Helicobacter pylori.  J Gastroenterol. 1999;  34 91-96
    PubMedGoogle Scholar
  • 38 Zullo A, Romiti A, Rinaldi V, et al. Gastric pathology in patients with common variable immunodeficiency.  Gut. 1999;  45 77-81
    CrossrefPubMedGoogle Scholar
  • 39 Kikuchi S, Hiki Y, Sakakibara Y, Kakita A, Kuwao S. Measuring the tumor volume of gastric carcinoma by computer image analysis: clinical significance.  World J Surg. 2000;  24 603-607
    CrossrefPubMedGoogle Scholar
  • 40 Ohashi S, Segawa K, Okamura S, et al. The utility of endoscopic ultrasonography and endoscopy in the endoscopic mucosal resection of early gastric cancer.  Gut. 1999;  45 599-604
    CrossrefPubMedGoogle Scholar
  • 41 Smith A, John T G, Garden O J, Brown S P. Role of laparoscopic ultrasonography in the management of patients with oesophagogastric cancer.  Br J Surg. 1999;  86 1083-1087
    CrossrefPubMedGoogle Scholar
  • 42 Feussner H, Omote K, Fink U, et al. Pretherapeutic laparoscopic staging in advanced gastric carcinoma.  Endoscopy. 1999;  31 342-347
    Article in Thieme ConnectPubMedGoogle Scholar
  • 43 Abe S, Izuishi K, Tajiri H, et al. Correlation of in vitro autofluorescence endoscopy images with histopathologic findings in stomach cancer.  Endoscopy. 2000;  32 281-286
    Article in Thieme ConnectPubMedGoogle Scholar
  • 44 Kitahara F, Kobayashi K, Sato T, et al. Accuracy of screening for gastric cancer using serum pepsinogen concentrations.  Gut. 1999;  44 693-697
    CrossrefPubMedGoogle Scholar
  • 45 Mayinger B, Reh H, Hochberger J, Hahn E G. Endoscopic photodynamic diagnosis: oral aminolevulinic acid is a marker of GI cancer and dysplastic lesions.  Gastrointest Endosc. 1999;  5 242-246
    PubMedGoogle Scholar
  • 46 Bramble M G, Suvakovic Z, Hungin A P. Detection of upper gastrointestinal cancer in patients taking antisecretory therapy prior to gastroscopy.  Gut. 2000 ;  46 464-467
    CrossrefPubMedGoogle Scholar
  • 47 Wayman J, Hayes N, Raimes S A, Griffin S M. Prescription of proton pump inhibitors before endoscopy: a potential cause of missed diagnosis of early gastric cancers.  Arch Fam Med. 2000;  9 385-388
    CrossrefPubMedGoogle Scholar
  • 48 Breslin N P, Thomson A B, Bailey R J, et al. Gastric cancer and other endoscopic diagnoses in patients with benign dyspepsia.  Gut. 2000;  46 93-97
    CrossrefPubMedGoogle Scholar
  • 49 Bini E J, Rajapaksa R C, Valdes M T, Weinshel E H. Is upper gastrointestinal endoscopy indicated in asymptomatic patients with a positive fecal occult blood test?.  Am J Med. 1999;  106 613-618
    CrossrefPubMedGoogle Scholar
  • 50 Nakamura K, Kamei T, Ohtomo N, et al. Gastric carcinoma confined to the muscularis propria: how can we detect, evaluate, and cure intermediate-stage carcinoma of the stomach?.  Am J Gastroenterol. 1999;  94 2251-2255
    CrossrefPubMedGoogle Scholar
  • 51 Yoshimura T, Shimoyama T, Fukuda S, et al. Most gastric cancer occurs on the distal side of the endoscopic atrophic border.  Scand J Gastroenterol. 1999;  34 1077-1081
    CrossrefPubMedGoogle Scholar
  • 52 Cammarota G, Cianci R, Pirozzi G, Gasbarrini G. Minimal endoscopic aspects of gastric low-grade malt-lymphoma.  Hepatogastroenterology. 1999;  46 2818-2822
    PubMedGoogle Scholar
  • 53 Morgner A, Lehn N, Andersen L P, et al. Helicobacter heilmannii-associated primary gastric low-grade MALT lymphoma: complete remission after curing the infection.  Gastroenterology. 2000;  118 821-828
    CrossrefPubMedGoogle Scholar
  • 54 Steinbach G, Ford R, Glober G, Sample D, et al. Antibiotic treatment of gastric lymphoma of mucosa-associated lymphoid tissue: an uncontrolled trial.  Ann Intern Med. 1999;  131 88-95
    CrossrefPubMedGoogle Scholar
  • 55 Weston A P, Banerjee S K, Horvat R. Prospective long-term endoscopic and histologic follow-up of gastric lymphoproliferative disease of early stage IE low-grade B-cell mucosa-associated lymphoid tissue type following Helicobacter pylori eradication treatment.  Int J Oncol. 1999;  15 899-907
    PubMedGoogle Scholar
  • 56 Chang D K, Chin Y J, Kim J S, et al. Lymph node involvement rate in low-grade gastric mucosa-associated lymphoid tissue lymphoma: too high to be neglected.  Hepatogastroenterology. 1999;  46 2694-2700
    PubMedGoogle Scholar
  • 57 Kojima T, Takahashi H, Parra-Blanco A, et al. Diagnosis of submucosal tumor of the upper GI tract by endoscopic resection.  Gastrointest Endosc. 1999;  5 516-522
    PubMedGoogle Scholar
  • 58 DeMatteo R P, Lewis J J, Leung D, et al. Two hundred gastrointestinal stromal tumors: recurrence patterns and prognostic factors for survival.  Ann Surg. 2000;  231 51-58
    CrossrefPubMedGoogle Scholar

M. Moretó,M.D. 

Gastroenterology Unit
Hospital de Cruces

Plaza de Cruces
48903 Baracaldo
Spain


Fax: Fax:+ 34-94-60063558

Email: E-mail:mmoretoc@meditex.es

      >